Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Active, not recruiting · NCT04798339 · Registry updated 2025-10-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2025-10-31 | NCT04798339 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
| Novartis Pharmaceuticals | 432 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory-Winship Cancer Institute | Atlanta | United States | 1 |
| Moffitt Cancer Center | Tampa | United States | 523 |